Cargando…

Adherence and Acceptability of an Oral Antibiotic Used for the Prevention of Pediatric Urinary Tract Infection in Japan

Urinary tract infection (UTI) is a common health care-associated adverse event and the leading nosocomial complication following pediatric urological surgery. While continuous antimicrobial prophylaxis effectively reduces the risk of UTI following such a surgery, non-adherence is common and represen...

Descripción completa

Detalles Bibliográficos
Autores principales: Saito, Jumpei, Miyamoto, Sayaka, Yamada, Mayumi, Yamatani, Akimasa, Ruiz, Fabrice, Vallet, Thibault
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8000562/
https://www.ncbi.nlm.nih.gov/pubmed/33800757
http://dx.doi.org/10.3390/pharmaceutics13030345
_version_ 1783671026619514880
author Saito, Jumpei
Miyamoto, Sayaka
Yamada, Mayumi
Yamatani, Akimasa
Ruiz, Fabrice
Vallet, Thibault
author_facet Saito, Jumpei
Miyamoto, Sayaka
Yamada, Mayumi
Yamatani, Akimasa
Ruiz, Fabrice
Vallet, Thibault
author_sort Saito, Jumpei
collection PubMed
description Urinary tract infection (UTI) is a common health care-associated adverse event and the leading nosocomial complication following pediatric urological surgery. While continuous antimicrobial prophylaxis effectively reduces the risk of UTI following such a surgery, non-adherence is common and represents a distinct clinical entity that is associated with renal scarring. Acceptability is likely to have a significant impact on patient adherence. Herein we used a validated data-driven approach—the ClinSearch acceptability score test (CAST)—to investigate the acceptability of cefaclor, an oral antibiotic widely used for the prevention of pediatric UTI in Japan. Standardized observer reports were collected for 58 intakes of cefaclor 10% fine granules in patients aged from 0 to 17 years. The medicine was classified as positively accepted on the acceptability reference framework. According to the percentage of the prescribed dose taken reported at the end of the treatment, patients exhibited good adherence to this well-accepted medicine. Nonetheless, requirements for greater dosing frequency or poor acceptability in certain patients could affect adherence. Acceptability should be established to ensure patient adherence to medicines used for long-term prophylaxis and consequently guarantee the safety and efficacy of the treatment.
format Online
Article
Text
id pubmed-8000562
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-80005622021-03-28 Adherence and Acceptability of an Oral Antibiotic Used for the Prevention of Pediatric Urinary Tract Infection in Japan Saito, Jumpei Miyamoto, Sayaka Yamada, Mayumi Yamatani, Akimasa Ruiz, Fabrice Vallet, Thibault Pharmaceutics Article Urinary tract infection (UTI) is a common health care-associated adverse event and the leading nosocomial complication following pediatric urological surgery. While continuous antimicrobial prophylaxis effectively reduces the risk of UTI following such a surgery, non-adherence is common and represents a distinct clinical entity that is associated with renal scarring. Acceptability is likely to have a significant impact on patient adherence. Herein we used a validated data-driven approach—the ClinSearch acceptability score test (CAST)—to investigate the acceptability of cefaclor, an oral antibiotic widely used for the prevention of pediatric UTI in Japan. Standardized observer reports were collected for 58 intakes of cefaclor 10% fine granules in patients aged from 0 to 17 years. The medicine was classified as positively accepted on the acceptability reference framework. According to the percentage of the prescribed dose taken reported at the end of the treatment, patients exhibited good adherence to this well-accepted medicine. Nonetheless, requirements for greater dosing frequency or poor acceptability in certain patients could affect adherence. Acceptability should be established to ensure patient adherence to medicines used for long-term prophylaxis and consequently guarantee the safety and efficacy of the treatment. MDPI 2021-03-06 /pmc/articles/PMC8000562/ /pubmed/33800757 http://dx.doi.org/10.3390/pharmaceutics13030345 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ).
spellingShingle Article
Saito, Jumpei
Miyamoto, Sayaka
Yamada, Mayumi
Yamatani, Akimasa
Ruiz, Fabrice
Vallet, Thibault
Adherence and Acceptability of an Oral Antibiotic Used for the Prevention of Pediatric Urinary Tract Infection in Japan
title Adherence and Acceptability of an Oral Antibiotic Used for the Prevention of Pediatric Urinary Tract Infection in Japan
title_full Adherence and Acceptability of an Oral Antibiotic Used for the Prevention of Pediatric Urinary Tract Infection in Japan
title_fullStr Adherence and Acceptability of an Oral Antibiotic Used for the Prevention of Pediatric Urinary Tract Infection in Japan
title_full_unstemmed Adherence and Acceptability of an Oral Antibiotic Used for the Prevention of Pediatric Urinary Tract Infection in Japan
title_short Adherence and Acceptability of an Oral Antibiotic Used for the Prevention of Pediatric Urinary Tract Infection in Japan
title_sort adherence and acceptability of an oral antibiotic used for the prevention of pediatric urinary tract infection in japan
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8000562/
https://www.ncbi.nlm.nih.gov/pubmed/33800757
http://dx.doi.org/10.3390/pharmaceutics13030345
work_keys_str_mv AT saitojumpei adherenceandacceptabilityofanoralantibioticusedforthepreventionofpediatricurinarytractinfectioninjapan
AT miyamotosayaka adherenceandacceptabilityofanoralantibioticusedforthepreventionofpediatricurinarytractinfectioninjapan
AT yamadamayumi adherenceandacceptabilityofanoralantibioticusedforthepreventionofpediatricurinarytractinfectioninjapan
AT yamataniakimasa adherenceandacceptabilityofanoralantibioticusedforthepreventionofpediatricurinarytractinfectioninjapan
AT ruizfabrice adherenceandacceptabilityofanoralantibioticusedforthepreventionofpediatricurinarytractinfectioninjapan
AT valletthibault adherenceandacceptabilityofanoralantibioticusedforthepreventionofpediatricurinarytractinfectioninjapan